ClinicalTrials.gg
CompletedNCT02139644Updated Nov 12, 2021Results posted

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

A Phase 3 interventional study of FS MDPI and Fp MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 140 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-12.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
787
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
13th of 146
787 · median 100
Started
2014
with 8 others
Phase 3
35 of 147
none open now
Registered
105th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 13th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2014, is one of 35 in phase 3, and was the 105th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when administered over 12 weeks in patients 12 years of age and older with persistent asthma.

Study drug and placebo was supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants performed spirometry at every visit. Each participant was given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) was dispensed at each visit, if needed, as determined by the investigational center personnel.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • fluticasone propionate
  • multidose dry powder inhaler
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Best pre-bronchodilator (FEV1) of 40 to 85% of their predicted normal value.
  2. Current Asthma Therapy: Patients must have a short-acting β2-agonist (for rescue use) for a minimum of 8 weeks before the Screening Visit (SV) and a low-dose inhaled (ICS). The low-dose ICS may be either as ICS monotherapy or as an ICS/long-acting beta agonist (LABA) combination. The ICS component of the patient's asthma therapy should be stable for a minimum of 1 months before providing consent.
  3. Reversibility of Disease: Patients must have at least 15% reversibility (all patients) and at least a 200 mL increase from baseline FEV1 (patients age 18 and older) within 30 minutes after 2 to 4 inhalations of albuterol/salbutamol at the SV. Note: Patients who do not qualify for the study due to failure to meet reversibility will be permitted to perform a retest once within 7 days.
  4. Patients must provide written /assent. For minor patients (ages 12 to 17 years, or as applicable per local regulations), the written ICF must be signed and dated by the parent/legal guardian and the written assent form must be signed and dated by the patient (if applicable). Note: Age requirements are as specified by local regulations.
  5. Outpatient >= 12 years of age on the date of consent/assent. In countries where the local regulations permit enrollment of adult patients only, patients must be 18 years of age and older.
  6. Asthma diagnosis: The patient has a diagnosis of asthma as defined by the National Institutes of Health (NIH). The asthma diagnosis has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in asthma medication) for at least 30 days.
  7. The patient is able to perform acceptable and repeatable spirometry.
  8. The patient is able to perform peak expiratory flow (PEF) with a handheld peak flow meter.
  9. The patient is able to use a MDI device without a spacer device and a MDPI device.
  10. The patient is able to withhold (as judged by the investigator) his or her regimen of ICS or study drug, and rescue medication for at least 6 hours before the SV and before all treatment visits.
  11. The patient/parent/legal guardian/caregiver is capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements.
  12. SABAs: All patients must be able to replace their current SABA with albuterol/salbutamol HFA MDI inhalation aerosol for the duration of the study.
  13. Female patients may not be pregnant, breastfeeding, or attempting to become pregnant.

    • other criteria may apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  1. A history of a life-threatening asthma exacerbation (an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures).
  2. The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the study.
  3. The patient has participated as a randomized patient in any drug study within 30 days of the SV.
  4. The patient has previously participated as a randomized patient in a study of Fp MDPI or FS MDPI.
  5. The patient has a known to any , salmeterol, or any of the in the study drug or rescue medication formulation (ie, lactose).
  6. The patient has been treated with any known strong cytochrome P450 (CYP) 3A4 inhibitors (eg, azole antifungals, ritonavir, or clarithromycin) within 30 days before the SV.
  7. The patient has been treated with any of the prohibited medications during the prescribed (per protocol) before the SV.
  8. The patient currently smokes or has a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient must not have used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco).
  9. The patient has a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that has not resolved at least 2 weeks before the SV.
  10. The patient has a history of alcohol or drug abuse within 2 years preceding the SV.
  11. The patient has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV, or has had any hospitalization for asthma within 2 months before the SV.
  12. Initiation or dose escalation of immunotherapy (administered by any route) is planned during the study period. However, patients on stable immunotherapy may be considered for inclusion.
  13. The patient has used medications within 4 weeks before the SV.
  14. The patient is unable to tolerate or unwilling to comply with the appropriate washout periods and withholding of all applicable medications.
  15. The patient has untreated oral candidiasis at the SV. Patients with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the study.
  16. The patient has a history of a positive test for (HIV), active virus, or infection.
  17. The patient is either an employee or an immediate relative of an employee of the clinical investigational center.
  18. A member of the patient's household is participating in the study at the same time. However, after the enrolled patient completes or discontinues participation in the study, another patient from the same household may be screened.
  19. The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.

    • other criteria may apply, please contact the investigator for more information
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
787 participants (actual)

Study arms

  • Experimental
    FS MDPI 100 / 12.5 mcg

    Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: FS MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate

  • Experimental
    FS MDPI 50 / 12.5 mcg

    Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: FS MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate

  • Experimental
    Fp MDPI 100 mcg

    Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: Fp MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate

  • Experimental
    Fp MDPI 50 mcg

    Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks. Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: Fp MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate

  • Placebo comparator
    Placebo MDPI

    The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Drug: Placebo MDPI · Drug: albuterol/salbutamol · Drug: Beclomethasone dipropionate

Interventions

  • FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx. Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.

    Also known as: fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist

  • Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg. Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.

    Also known as: fluticasone propionate, inhaled corticosteroid

  • DrugPlacebo MDPI

    Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.

    Also known as: inert powder

  • Drugalbuterol/salbutamol

    Drug page: Albuterol

    A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

    Also known as: short-acting β2-adrenergic agonists

  • QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.

    Also known as: QVAR

06

What researchers measure

Primary outcomes

  1. Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12

    A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Data from these assessments were used to analyze the primary endpoint of baseline adjusted FEV1 AUEC0-12h at week 12 using the trapezoidal rule based on actual time of measurement. It was standardized by dividing it by the number of hours between the start time of dose administration and the end time of the last nonmissing FEV1 measurement. The baseline FEV1 was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose). If 1 of these was missing, the nonmissing value was used; if both were missing, baseline was treated as missing. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting the baseline FEV1 value.

    Time frame: Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours

  2. Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12

    Trough FEV1 was a morning spirometry taken predose and pre-rescue bronchodilator. If the patient inadvertently administered asthma medication/study drug at home on the AM of the visit, or if the patient took rescue medication within 6 hours of testing, the visit was rescheduled. The baseline for predose FEV1 was defined as the average of the 30-minute and 10-minute predose measurements obtained at the randomization visit (Day 1).

    Time frame: Day 1 (predose, baseline), Week 12

Secondary outcomes

  1. Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment

    Morning PEF tests were performed before administration of study drug or rescue medications (data were excluded if the time of PEF measurement was more than 5 minutes after the dose time). The patient recorded the highest value of 3 measurements obtained in the patient diary. The baseline PEF was the average value of recorded (nonmissing) morning assessments over the 7 days prior to randomization on Day 1. For efficacy analyses of weekly average morning PEF measurements, values were the averages based on available data for that week.

    Time frame: Days -6 to Day 1 (predose), Day 1 (postdose) daily until Week 12

  2. Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period

    The total daily asthma symptom score is the average of the daytime and nighttime scores as recorded in the patient diary (range 0-9). Daytime Symptom Score: 0=No symptoms 1. Symptoms for 1 short period 2. Symptoms for 2+ short periods 3. Symptoms for most of the day - did not affect normal daily activities 4. Symptoms for most of the day - did affect normal daily activities 5. Symptoms so severe that I could not go to work or perform normal daily activities Nighttime Symptom Score (determined in the AM): 0=No symptoms 1. Symptoms causing me to wake once (or wake early) 2. Symptoms causing me to wake twice or more (including waking early) 3. Symptoms causing me to be awake for most of the night 4. Symptoms so severe that I did not sleep Baseline was the average of recorded scores over the 7 days before randomization. The change from baseline in the weekly average over weeks 1 to 12 was analyzed using an mixed model for repeated measures (MMRM).

    Time frame: Days -6 to Day 1 (predose, baseline) to Week 12

  3. Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period

    Patients recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each AM and PM in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value. The weekly average was based on the available data for the 7 days before each analysis week. The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) over weeks 1 to 12 was analyzed using a mixed model for repeated measures.

    Time frame: Days -6 to Day 1 (predose, baseline), up to week 12

  4. Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12

    The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma, defined as the number of days elapsed from the date of randomization to the date of withdrawal due to worsening asthma. Patients who were lost to follow-up, who had not withdrawn due to worsening asthma by week 12, or who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.

    Time frame: up to Week 12 of the Treatment Period

  5. Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old

    The AQLQ(S) (September 2010 version; patients aged ≥18 years) was self-administered by the patients at the investigational center at the randomization visit and at Week 12 or end of trial. The questionnaire is a tool to measure the impact of asthma on a patient's quality of life (physical, emotional, social, and occupational) with a recall period of 2 weeks. The AQLQ(S) was administered only to patients 18 years and older. The 32 individual questions in the AQLQ were equally weighted. The overall AQLQ score was the mean of the responses to each of the 32 questions, and ranged from 1 to 7. A score of 7.0 indicated that the patient had no impairments due to asthma and a score of 1.0 indicated severe impairment. Positive change from baseline scores indicate improved quality of life.

    Time frame: Day 1 (predose, baseline), end of trial (up to week 12)

  6. Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1

    A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Baseline FEV1 was the average of 2 FEV1 measurements (30 and 10 minutes predose) on Day 1. If one of these was missing, the other measurement was used as baseline value. If both were missing, baseline was treated as missing. Time to target improvement (15% or 12%) was defined as the time elapsed from the time of first dose to the first time the target improvement in FEV1 was achieved. If an exact target increase was not achieved at a measured timepoint, then the time was estimated by linear interpolation between the timepoint when target was reached and the timepoint immediately before. Patients who did not achieve the target improvement were censored at the time of last serial spirometry assessment. Values of 9999 indicate the values could not be estimated which happened when the estimated probability of not achieving target is more than 50%.

    Time frame: Day 1 of the Treatment Period (predose and postdose)

  7. Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Time frame: Day 1 to Week 12 of the Treatment Period

07

Results

Posted Apr 12, 2017

Participant flow

A total of 1363 patients with persistent asthma were screened for enrollment into this study. 787 patients at 129 investigational centers in the US and elsewhere internationally met entry criteria and were considered eligible for enrollment into the study.

Run-In Period (Pre-assignment)
Participant flow — Run-In Period (Pre-assignment)
MilestoneEnrolled PatientsFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Started78700000
Completed64700000
Not completed14000000
Withdrew: Randomization criteria not met7000000
Withdrew: Inclusion criteria not met3000000
Withdrew: Withdrawal by subject1200000
Withdrew: Exclusion criteria met1100000
Withdrew: Lost to follow-up800000
Withdrew: Adverse event300000
Withdrew: Other600000
Treatment Period
Participant flow — Treatment Period
MilestoneEnrolled PatientsFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Started0129129130129130
Completed0126121121121113
Not completed0389817
Withdrew: Adverse event003216
Withdrew: Withdrawal by subject002232
Withdrew: Non-compliance000100
Withdrew: Protocol violation000111
Withdrew: Disease progression000112
Withdrew: Lost to follow-up001111
Withdrew: Lack of efficacy001014
Withdrew: Other031101

Outcome measures

PrimaryStandardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12

A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Data from these assessments were used to analyze the primary endpoint of baseline adjusted FEV1 AUEC0-12h at week 12 using the trapezoidal rule based on actual time of measurement. It was standardized by dividing it by the number of hours between the start time of dose administration and the end time of the last nonmissing FEV1 measurement. The baseline FEV1 was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose). If 1 of these was missing, the nonmissing value was used; if both were missing, baseline was treated as missing. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting the baseline FEV1 value.

Time frame:
Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours
Reported as:
Least squares mean · liters
Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12
litersFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 120.408 ± 0.04650.399 ± 0.04790.254 ± 0.04340.268 ± 0.04570.074 ± 0.0487
Statistical analysis
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · ANCOVA · p = 0.0076 · Lsm difference: 0.154 · 95% CI 0.041 to 0.267Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 50 mcg · ANCOVA · p = 0.0322 · Lsm difference: 0.131 · 95% CI 0.011 to 0.250Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 · Lsm difference: 0.335 · 95% CI 0.216 to 0.453Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.
  • FS MDPI 50 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 · Lsm difference: 0.325 · 95% CI 0.203 to 0.447Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.
PrimaryChange From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12

Trough FEV1 was a morning spirometry taken predose and pre-rescue bronchodilator. If the patient inadvertently administered asthma medication/study drug at home on the AM of the visit, or if the patient took rescue medication within 6 hours of testing, the visit was rescheduled. The baseline for predose FEV1 was defined as the average of the 30-minute and 10-minute predose measurements obtained at the randomization visit (Day 1).

Time frame:
Day 1 (predose, baseline), Week 12
Reported as:
Least squares mean · liters
Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
litersFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 120.315 ± 0.03520.319 ± 0.03500.204 ± 0.03400.172 ± 0.03470.053 ± 0.0350
Statistical analysis
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 · Lsm difference: 0.262 · 95% CI 0.168 to 0.356Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.
  • FS MDPI 50 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 · Lsm difference: 0.266 · 95% CI 0.172 to 0.360Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.
  • Fp MDPI 100 mcg vs Placebo MDPI · ANCOVA · p = 0.0017 · Lsm difference: 0.151 · 95% CI 0.057 to 0.244Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.
  • Fp MDPI 50 mcg vs Placebo MDPI · ANCOVA · p = 0.0132 · Lsm difference: 0.119 · 95% CI 0.025 to 0.212Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.
SecondaryChange From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment

Morning PEF tests were performed before administration of study drug or rescue medications (data were excluded if the time of PEF measurement was more than 5 minutes after the dose time). The patient recorded the highest value of 3 measurements obtained in the patient diary. The baseline PEF was the average value of recorded (nonmissing) morning assessments over the 7 days prior to randomization on Day 1. For efficacy analyses of weekly average morning PEF measurements, values were the averages based on available data for that week.

Time frame:
Days -6 to Day 1 (predose), Day 1 (postdose) daily until Week 12
Reported as:
Least squares mean · liters/minute
Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment
liters/minuteFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment24.415 ± 3.153024.864 ± 3.118214.517 ± 3.077810.609 ± 3.11763.591 ± 3.1474
Statistical analysis
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0123 (Significance level of 0.05.) · Lsm difference: 10.926 · 95% CI 2.380 to 19.471
  • Fp MDPI 50 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.1074 (Significance level of 0.05.) · Lsm difference: 7.018 · 95% CI -1.531 to 15.567
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 20.824 · 95% CI 12.253 to 29.395
  • FS MDPI 50 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 21.273 · 95% CI 12.728 to 29.818
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.0233 (Significance level of 0.05.) · Lsm difference: 9.898 · 95% CI 1.349 to 18.447
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 50 mcg · mixed model for repeated measures · p = 0.0011 (Significance level of 0.05.) · Lsm difference: 14.255 · 95% CI 5.732 to 22.778
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.0175 (Significance level of 0.05.) · Lsm difference: 10.347 · 95% CI 1.822 to 18.872
SecondaryChange From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period

The total daily asthma symptom score is the average of the daytime and nighttime scores as recorded in the patient diary (range 0-9). Daytime Symptom Score: 0=No symptoms 1. Symptoms for 1 short period 2. Symptoms for 2+ short periods 3. Symptoms for most of the day - did not affect normal daily activities 4. Symptoms for most of the day - did affect normal daily activities 5. Symptoms so severe that I could not go to work or perform normal daily activities Nighttime Symptom Score (determined in the AM): 0=No symptoms 1. Symptoms causing me to wake once (or wake early) 2. Symptoms causing me to wake twice or more (including waking early) 3. Symptoms causing me to be awake for most of the night 4. Symptoms so severe that I did not sleep Baseline was the average of recorded scores over the 7 days before randomization. The change from baseline in the weekly average over weeks 1 to 12 was analyzed using an mixed model for repeated measures (MMRM).

Time frame:
Days -6 to Day 1 (predose, baseline) to Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
units on a scaleFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period-0.364 ± 0.0318-0.329 ± 0.0314-0.300 ± 0.0308-0.278 ± 0.0314-0.135 ± 0.0318
Statistical analysis
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0002 (Significance level of 0.05.) · Lsm difference: -0.165 · 95% CI -0.251 to -0.080
  • Fp MDPI 50 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0010 (Significance level of 0.05.) · Lsm difference: -0.143 · 95% CI -0.229 to -0.058
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -0.230 · 95% CI -0.315 to -0.144
  • FS MDPI 50 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -0.194 · 95% CI -0.279 to -0.109
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.1381 (Significance level of 0.05.) · Lsm difference: -0.064 · 95% CI -0.150 to 0.021
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 50 mcg · mixed model for repeated measures · p = 0.2438 (Significance level of 0.05.) · Lsm difference: -0.051 · 95% CI -0.136 to 0.035
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.5095 (Significance level of 0.05.) · Lsm difference: -0.029 · 95% CI -0.114 to 0.057
SecondaryChange From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period

Patients recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each AM and PM in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value. The weekly average was based on the available data for the 7 days before each analysis week. The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) over weeks 1 to 12 was analyzed using a mixed model for repeated measures.

Time frame:
Days -6 to Day 1 (predose, baseline), up to week 12
Reported as:
Least squares mean · puffs
Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period
puffsFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period-0.677 ± 0.0937-0.706 ± 0.0930-0.466 ± 0.0915-0.467 ± 0.0928-0.003 ± 0.0937
Statistical analysis
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0004 (Significance level of 0.05) · Lsm difference: -0.463 · 95% CI -0.716 to -0.209
  • Fp MDPI 50 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0003 (Significance level of 0.05) · Lsm difference: -0.464 · 95% CI -0.718 to -0.211
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05) · Lsm difference: -0.675 · 95% CI -0.928 to -0.421
  • FS MDPI 50 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05) · Lsm difference: -0.704 · 95% CI -0.957 to -0.450
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.1014 (Significance level of 0.05) · Lsm difference: -0.212 · 95% CI -0.465 to 0.042
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 50 mcg · mixed model for repeated measures · p = 0.0640 (Significance level of 0.05) · Lsm difference: -0.239 · 95% CI -0.492 to 0.014
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.0626 (Significance level of 0.05) · Lsm difference: -0.241 · 95% CI -0.494 to 0.013
SecondaryKaplan-Meier Estimate of Probability of Remaining in Study At Week 12

The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma, defined as the number of days elapsed from the date of randomization to the date of withdrawal due to worsening asthma. Patients who were lost to follow-up, who had not withdrawn due to worsening asthma by week 12, or who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.

Time frame:
up to Week 12 of the Treatment Period
Reported as:
Number · probability
Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12
probabilityFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Kaplan-Meier Estimate of Probability of Remaining in Study At Week 121.0000 (1.000 to 1.000)0.9917 (0.942 to 0.999)0.9919 (0.944 to 0.999)0.9919 (0.944 to 0.999)0.9681 (0.917 to 0.988)
Statistical analysis
  • Fp MDPI 100 mcg vs Placebo MDPI · Log Rank · p = 0.1679 (Significance level of 0.05)
  • Fp MDPI 50 mcg vs Placebo MDPI · Log Rank · p = 0.1701 (Significance level of 0.05)
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · Log Rank · p = 0.0437 (Significance level of 0.05)
  • FS MDPI 50 / 12.5 mcg vs Placebo MDPI · Log Rank · p = 0.1718 (Significance level of 0.05)
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · Log Rank · p = 0.3134 (Significance level of 0.05)
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 50 mcg · Log Rank · p = 0.9930 (Significance level of 0.05)
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 100 mcg · Log Rank · p = 0.9999 (Significance level of 0.05)
SecondaryChange From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old

The AQLQ(S) (September 2010 version; patients aged ≥18 years) was self-administered by the patients at the investigational center at the randomization visit and at Week 12 or end of trial. The questionnaire is a tool to measure the impact of asthma on a patient's quality of life (physical, emotional, social, and occupational) with a recall period of 2 weeks. The AQLQ(S) was administered only to patients 18 years and older. The 32 individual questions in the AQLQ were equally weighted. The overall AQLQ score was the mean of the responses to each of the 32 questions, and ranged from 1 to 7. A score of 7.0 indicated that the patient had no impairments due to asthma and a score of 1.0 indicated severe impairment. Positive change from baseline scores indicate improved quality of life.

Time frame:
Day 1 (predose, baseline), end of trial (up to week 12)
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old
units on a scaleFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old0.808 ± 0.07280.565 ± 0.07520.636 ± 0.07360.588 ± 0.07330.335 ± 0.0777
Statistical analysis
  • Fp MDPI 100 mcg vs Placebo MDPI · ANCOVA · p = 0.0044 (Significance level of 0.05) · Lsm difference: 0.301 · 95% CI 0.094 to 0.508
  • Fp MDPI 50 mcg vs Placebo MDPI · ANCOVA · p = 0.0155 (Significance level of 0.05) · Lsm difference: 0.253 · 95% CI 0.048 to 0.458
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Significance level of 0.05) · Lsm difference: 0.473 · 95% CI 0.270 to 0.676
  • FS MDPI 50 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0293 (Significance level of 0.05) · Lsm difference: 0.230 · 95% CI 0.023 to 0.437
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · ANCOVA · p = 0.0913 (Significance level of 0.05) · Lsm difference: 0.172 · 95% CI -0.028 to 0.372
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 50 mcg · ANCOVA · p = 0.8216 (Significance level of 0.05) · Lsm difference: -0.023 · 95% CI -0.223 to 0.177
  • FS MDPI 50 / 12.5 mcg vs Fp MDPI 100 mcg · ANCOVA · p = 0.4934 (Significance level of 0.05) · Lsm difference: -0.071 · 95% CI -0.275 to 0.133
SecondaryKaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1

A subset of approximately 300 patients who performed postdose serial spirometry is based on sample size calculation. Baseline FEV1 was the average of 2 FEV1 measurements (30 and 10 minutes predose) on Day 1. If one of these was missing, the other measurement was used as baseline value. If both were missing, baseline was treated as missing. Time to target improvement (15% or 12%) was defined as the time elapsed from the time of first dose to the first time the target improvement in FEV1 was achieved. If an exact target increase was not achieved at a measured timepoint, then the time was estimated by linear interpolation between the timepoint when target was reached and the timepoint immediately before. Patients who did not achieve the target improvement were censored at the time of last serial spirometry assessment. Values of 9999 indicate the values could not be estimated which happened when the estimated probability of not achieving target is more than 50%.

Time frame:
Day 1 of the Treatment Period (predose and postdose)
Reported as:
Median · hours
Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1
hoursFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
15% improvement4.3 (1.070 to NA)1.3 (0.600 to 2.750)NA (10.190 to NA)NA (NA to NA)NA (NA to NA)
12% improvement1.0 (0.460 to 3.720)0.5 (0.300 to 1.550)NA (7.370 to NA)NA (3.890 to NA)NA (7.270 to NA)
SecondaryPatients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Time frame:
Day 1 to Week 12 of the Treatment Period
Reported as:
Count of participants · Participants
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
ParticipantsFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
>=1 TEAE3746404447
>=1 severe TEAE20110
>=1 treatment-related TEAE44575
>=1 severe treatment-related TEAE00000
>=1 serious TEAE10102
>=1 TEAE leading to withdrawal03216
>=1 nonserious TEAE3646394445
>=1 TEAE resulting in death00000

Adverse events

Collected over Day 1 up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FS MDPI 100 / 12.5 mcg—1/126 (0.8%)12/126 (9.5%)
FS MDPI 50 / 12.5 mcg—0/128 (0%)22/128 (17.2%)
Fp MDPI 100 mcg—1/129 (0.8%)21/129 (16.3%)
Fp MDPI 50 mcg—0/129 (0%)15/129 (11.6%)
Placebo MDPI—2/129 (1.6%)15/129 (11.6%)
Most frequent serious events
Most frequent serious events
EventFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
PancreatitisGastrointestinal disorders1/1260/1280/1290/1290/129
CholecystitisHepatobiliary disorders1/1260/1280/1290/1290/129
CholelithiasisHepatobiliary disorders1/1260/1280/1290/1290/129
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1260/1281/1290/1290/129
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1260/1280/1290/1291/129
AsthmaRespiratory, thoracic and mediastinal disorders0/1260/1280/1290/1291/129
Most frequent other events
Most frequent other events
EventFS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPI
NasopharyngitisInfections and infestations3/12611/1289/1297/1294/129
HeadacheNervous system disorders7/1267/1289/1292/1295/129
Upper respiratory tract infectionInfections and infestations2/1266/1284/1297/1296/129

Baseline characteristics

Intent to treat population

Age, Continuous
Age, Continuous(years)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
Mean41.0 ± 17.0041.4 ± 18.6140.6 ± 17.1643.3 ± 17.9640.9 ± 17.3541.5 ± 17.60
Age, Customized
Age, Customized(Participants)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
Adolescents (12-17 years)191918131786
Adults (18-64 years)1009710293102494
Adults (65+ years)101310231167
Sex: Female, Male
Sex: Female, Male(Participants)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
Female7271767570364
Male5758545460283
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
White10510993107101515
Black or African American2019301826113
Asian4141111
American Indian or Alaskan Native001001
Native Hawaiian or Other Pacific Islander000101
Other002226
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
Not Hispanic or Latino119121114121122597
Hispanic or Latino108168749
Unknown000011
Body Mass Index
Body Mass Index(kg/m^2)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
Mean27.94 ± 6.68628.00 ± 7.16627.63 ± 6.60327.94 ± 7.25927.99 ± 6.84927.90 ± 6.897
History of Smoking
History of Smoking(Participants)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
Prior smoker181315141272
No tobacco use111116115115118575
Previous Asthma Therapy
Previous Asthma Therapy(Participants)FS MDPI 100 / 12.5 mcgFS MDPI 50 / 12.5 mcgFp MDPI 100 mcgFp MDPI 50 mcgPlacebo MDPITotal
Inhaled corticosteroid97908389102461
Inhaled corticosteroid/long-acting beta2-agonist3239474028186

1 further baseline measures are reported on the registry.

08

Study locations

140 sites
  • Teva Investigational Site 12397
    Birmingham, Alabama, United States
  • Teva Investigational Site 12375
    Glendale, Arizona, United States
  • Teva Investigational Site 12395
    Cypress, California, United States
  • Teva Investigational Site 12476
    Encinitas, California, United States
  • Teva Investigational Site 12586
    Fountain Valley, California, United States
  • Teva Investigational Site 12591
    Fresno, California, United States
  • Teva Investigational Site 12372
    Huntington Beach, California, United States
  • Teva Investigational Site 12365
    Los Angeles, California, United States
  • Teva Investigational Site 12381
    Los Angeles, California, United States
  • Teva Investigational Site 12401
    Los Angeles, California, United States
  • Teva Investigational Site 12394
    Mission Viejo, California, United States
  • Teva Investigational Site 12490
    Rancho Mirage, California, United States
  • Teva Investigational Site 12393
    Riverside, California, United States
  • Teva Investigational Site 12366
    Rolling Hills Estates, California, United States
  • Teva Investigational Site 12383
    San Diego, California, United States
  • Teva Investigational Site 12370
    San Jose, California, United States
  • Teva Investigational Site 12371
    Stockton, California, United States
  • Teva Investigational Site 12579
    Upland, California, United States
  • Teva Investigational Site 12379
    Centennial, Colorado, United States
  • Teva Investigational Site 12386
    Centennial, Colorado, United States
  • Teva Investigational Site 12596
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 12584
    Longmont, Colorado, United States
  • Teva Investigational Site 12484
    Waterbury, Connecticut, United States
  • Teva Investigational Site 12590
    Waterbury, Connecticut, United States
  • Teva Investigational Site 12493
    Clearwater, Florida, United States
  • Teva Investigational Site 12992
    Largo, Florida, United States
  • Teva Investigational Site 12376
    Miami, Florida, United States
  • Teva Investigational Site 12390
    Miami, Florida, United States
  • Teva Investigational Site 12583
    Orlando, Florida, United States
  • Teva Investigational Site 12481
    Tallahassee, Florida, United States
  • Teva Investigational Site 12491
    Winter Park, Florida, United States
  • Teva Investigational Site 12997
    Decatur, Georgia, United States
  • Teva Investigational Site 12392
    Savannah, Georgia, United States
  • Teva Investigational Site 12592
    Shiloh, Illinois, United States
  • Teva Investigational Site 12483
    Lenexa, Kansas, United States
  • Teva Investigational Site 12399
    Baltimore, Maryland, United States
  • Teva Investigational Site 12391
    Bethesda, Maryland, United States
  • Teva Investigational Site 12589
    Columbia, Maryland, United States
  • Teva Investigational Site 12369
    Rockville, Maryland, United States
  • Teva Investigational Site 12396
    Fall River, Massachusetts, United States
  • Teva Investigational Site 12384
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 12585
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 12588
    Ypsilanti, Michigan, United States
  • Teva Investigational Site 12494
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12595
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12594
    Missoula, Montana, United States
  • Teva Investigational Site 12385
    Ocean City, New Jersey, United States
  • Teva Investigational Site 12380
    Skillman, New Jersey, United States
  • Teva Investigational Site 12587
    Brooklyn, New York, United States
  • Teva Investigational Site 12485
    Rockville Centre, New York, United States
  • Teva Investigational Site 12475
    Huntersville, North Carolina, United States
  • Teva Investigational Site 12364
    Raleigh, North Carolina, United States
  • Teva Investigational Site 12374
    Canton, Ohio, United States
  • Teva Investigational Site 12480
    Cincinnati, Ohio, United States
  • Teva Investigational Site 12492
    Cincinnati, Ohio, United States
  • Teva Investigational Site 12487
    Middleburg Heights, Ohio, United States
  • Teva Investigational Site 12488
    Sylvania, Ohio, United States
  • Teva Investigational Site 12377
    Edmond, Oklahoma, United States
  • Teva Investigational Site 12368
    Medford, Oregon, United States
  • Teva Investigational Site 12382
    Portland, Oregon, United States
  • Teva Investigational Site 12400
    Pittsburgh, Pennsylvania, United States
  • Teva Investigational Site 12473
    Upland, Pennsylvania, United States
  • Teva Investigational Site 12389
    Greenville, South Carolina, United States
  • Teva Investigational Site 12580
    Mount Pleasant, South Carolina, United States
  • Teva Investigational Site 12398
    Orangeburg, South Carolina, United States
  • Teva Investigational Site 12991
    Knoxville, Tennessee, United States
  • Teva Investigational Site 12990
    Cypress, Texas, United States
  • Teva Investigational Site 12373
    Dallas, Texas, United States
  • Teva Investigational Site 12402
    El Paso, Texas, United States
  • Teva Investigational Site 12582
    New Braunfels, Texas, United States
  • Teva Investigational Site 12363
    San Antonio, Texas, United States
  • Teva Investigational Site 12482
    San Antonio, Texas, United States
  • Teva Investigational Site 12477
    Waco, Texas, United States
  • Teva Investigational Site 12478
    Murray, Utah, United States
  • Teva Investigational Site 12388
    South Burlington, Vermont, United States
  • Teva Investigational Site 12378
    Milwaukee, Wisconsin, United States
  • Teva Investigational Site 11065
    Toronto, Ontario, Canada
  • Teva Investigational Site 11067
    Montreal, Quebec, Canada
  • Teva Investigational Site 11068
    Vancouver, Quebec, Canada
  • Teva Investigational Site 54084
    Neratovice, Czechia
  • Teva Investigational Site 54088
    Praha, Czechia
  • Teva Investigational Site 54087
    Rokycany, Czechia
  • Teva Investigational Site 51134
    Budapest, Hungary
  • Teva Investigational Site 51143
    Budapest, Hungary
  • Teva Investigational Site 51144
    Budapest, Hungary
  • Teva Investigational Site 51140
    Debrecen, Hungary
  • Teva Investigational Site 51142
    Deszk, Hungary
  • Teva Investigational Site 51165
    Dombovar, Hungary
  • Teva Investigational Site 51145
    Kiskunhalas, Hungary
  • Teva Investigational Site 51141
    Miskolc, Hungary
  • Teva Investigational Site 51133
    Mosdós, Hungary
  • Teva Investigational Site 51136
    Nyíregyháza, Hungary
  • Teva Investigational Site 51139
    Nyíregyháza, Hungary
  • Teva Investigational Site 51163
    Sopron, Hungary
  • Teva Investigational Site 51137
    Szeged, Hungary
  • Teva Investigational Site 51164
    Szigetvár, Hungary
  • Teva Investigational Site 51138
    Szombathely, Hungary
  • Teva Investigational Site 53182
    Bialystok, Poland
  • Teva Investigational Site 53183
    Bialystok, Poland
  • Teva Investigational Site 53185
    Bialystok, Poland

Showing the first 100 of 140 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Raphael G, Yiu G, Sakov A, Liu S, Caracta C. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older. J Asthma. 2018 Jun;55(6):640-650. doi: 10.1080/02770903.2017.1350971. Epub 2017 Aug 31. PubMed 28763243 ↗
  • Miller DS, Yiu G, Hellriegel ET, Steinfeld J. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. Allergy Asthma Proc. 2016 Jul;37(4):291-301. doi: 10.2500/aap.2016.37.3963. Epub 2016 May 27. PubMed 27216137 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2014
First posted
May 15, 2014
Start
Jun 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Apr 12, 2017
Last update
Nov 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02139644
Responsible party
Sponsor
First posted
May 15, 2014
Start date
Jun 2014
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Apr 12, 2017
Last update
Nov 12, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion